A. Bruce Montgomery

6.8k total citations · 1 hit paper
55 papers, 4.6k citations indexed

About

A. Bruce Montgomery is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Critical Care and Intensive Care Medicine. According to data from OpenAlex, A. Bruce Montgomery has authored 55 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 20 papers in Epidemiology and 9 papers in Critical Care and Intensive Care Medicine. Recurrent topics in A. Bruce Montgomery's work include Cystic Fibrosis Research Advances (30 papers), Inhalation and Respiratory Drug Delivery (23 papers) and Pneumonia and Respiratory Infections (15 papers). A. Bruce Montgomery is often cited by papers focused on Cystic Fibrosis Research Advances (30 papers), Inhalation and Respiratory Drug Delivery (23 papers) and Pneumonia and Respiratory Infections (15 papers). A. Bruce Montgomery collaborates with scholars based in United States, Australia and United Kingdom. A. Bruce Montgomery's co-authors include Alexandra L. Quittner, Kelly Otto, Bonnie W. Ramsey, Arnold L. Smith, Christopher M. Oermann, Karen McCoy, Margaret S. Pepe, George Retsch‐Bogart, Joanne Quan and Ronald L. Gibson and has published in prestigious journals such as New England Journal of Medicine, JAMA and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

A. Bruce Montgomery

55 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis

1999 974 citations Bonnie W. Ramsey, Margaret S. Pepe et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Bruce Montgomery United States	28	3.7k	1.3k	615	574	528	55	4.6k
Harry Heijerman Netherlands	34	3.8k 1.0×	826 0.6×	205 0.3×	545 0.9×	385 0.7×	145	5.0k
Jordi Dorca Spain	44	1.6k 0.4×	3.5k 2.7×	1.1k 1.9×	324 0.6×	402 0.8×	143	5.5k
S.P. Conway United Kingdom	35	2.8k 0.8×	774 0.6×	124 0.2×	515 0.9×	277 0.5×	90	3.9k
Oriol Sibila Spain	32	2.1k 0.6×	1.3k 1.0×	491 0.8×	189 0.3×	453 0.9×	153	3.9k
George Retsch‐Bogart United States	35	3.0k 0.8×	602 0.5×	214 0.3×	353 0.6×	368 0.7×	66	3.4k
Nobuaki Shime Japan	29	975 0.3×	778 0.6×	625 1.0×	404 0.7×	142 0.3×	233	2.9k
Drucy Borowitz United States	38	6.1k 1.7×	767 0.6×	125 0.2×	211 0.4×	541 1.0×	115	7.3k
Jeffrey S. Wagener United States	41	5.2k 1.4×	926 0.7×	138 0.2×	185 0.3×	663 1.3×	98	6.3k
Margaret M. Johnson United States	30	1.4k 0.4×	1.0k 0.8×	729 1.2×	134 0.2×	187 0.4×	113	4.1k
Ilias Ι. Siempos Greece	38	1.4k 0.4×	1.3k 1.0×	1.0k 1.7×	289 0.5×	103 0.2×	94	3.7k

Countries citing papers authored by A. Bruce Montgomery

Since Specialization

Citations

This map shows the geographic impact of A. Bruce Montgomery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Bruce Montgomery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Bruce Montgomery more than expected).

Fields of papers citing papers by A. Bruce Montgomery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Bruce Montgomery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Bruce Montgomery. The network helps show where A. Bruce Montgomery may publish in the future.

Co-authorship network of co-authors of A. Bruce Montgomery

This figure shows the co-authorship network connecting the top 25 collaborators of A. Bruce Montgomery. A scholar is included among the top collaborators of A. Bruce Montgomery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Bruce Montgomery. A. Bruce Montgomery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weiss, Anne, Robert J. Bischof, Cornelia B. Landersdorfer, et al.. (2023). Single-dose pharmacokinetics and lung function of nebulized niclosamide ethanolamine in sheep. Pharmaceutical Research. 40(8). 1915–1925. 3 indexed citations

West, Alex, Nazia Chaudhuri, Adam Barczyk, et al.. (2023). Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial. Thorax. 78(9). 882–889. 35 indexed citations

Montgomery, A. Bruce, et al.. (2019). A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33(1). 15–20. 30 indexed citations

Kaminskas, Lisa M., et al.. (2019). Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis. Pharmaceutical Research. 37(1). 3–3. 23 indexed citations

Montgomery, A. Bruce, et al.. (2018). Late Breaking Abstract - Phase 1 dose escalation study of aerosolized pirfenidone in normal healthy volunteers (NHV), smokers, and IPF patients. OA266–OA266. 2 indexed citations

Sime, Fekade B., Adam Johnson, Sarah Whalley, et al.. (2016). Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. Antimicrobial Agents and Chemotherapy. 61(1). 23 indexed citations

Montgomery, A. Bruce, et al.. (2014). A Randomized Double-Blind Placebo-Controlled Dose-Escalation Phase 1 Study of Aerosolized Amikacin and Fosfomycin Delivered via the PARI Investigational eFlow ^® Inline Nebulizer System in Mechanically Ventilated Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 27(6). 441–448. 59 indexed citations

Barker, Alan F., Anne E. O’Donnell, Patrick A. Flume, et al.. (2014). Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. The Lancet Respiratory Medicine. 2(9). 738–749. 153 indexed citations

Raghu, Ganesh, David A. Lynch, J. David Godwin, et al.. (2014). Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. The Lancet Respiratory Medicine. 2(4). 277–284. 136 indexed citations

10.

O’Riordan, Thomas G., Peter Hodsman, John H. Ansede, et al.. (2013). Acute Hyperkalemia Associated with Inhalation of a Potent ENaC Antagonist: Phase 1 Trial of GS-9411. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 27(3). 200–208. 45 indexed citations

11.

Barker, Alan R., Anne O’Donnell, Philip J. Thompson, et al.. (2013). Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB). European Respiratory Journal. 42(Suppl 57). P4136–P4136. 10 indexed citations

12.

Montgomery, A. Bruce, et al.. (2012). Regulatory Aspects of Phase 3 Endpoints for New Inhaled Antibiotics for Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 25(4). 198–203. 9 indexed citations

13.

Trapnell, Bruce C., Susanna A. McColley, Dana G. Kissner, et al.. (2011). Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis with Pseudomonas Airway Infection. American Journal of Respiratory and Critical Care Medicine. 185(2). 171–178. 103 indexed citations

14.

Wainwright, Claire, et al.. (2011). Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. Journal of Cystic Fibrosis. 10(4). 234–242. 71 indexed citations

15.

Abuan, Tammy, et al.. (2010). Inhaled Lidocaine for the Treatment of Asthma: Lack of Efficacy in Two Double-Blind, Randomized, Placebo-Controlled Clinical Studies. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 23(6). 381–388. 11 indexed citations

16.

McCoy, Karen, et al.. (2009). Efficacy of Aztreonam Lysine for Inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA). Journal of Cystic Fibrosis. 8. S28–S28. 10 indexed citations

17.

Retsch‐Bogart, George, Alexandra L. Quittner, Ronald L. Gibson, et al.. (2009). Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis. CHEST Journal. 135(5). 1223–1232. 214 indexed citations

18.

McCoy, Karen, Alexandra L. Quittner, Christopher M. Oermann, et al.. (2008). Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 178(9). 921–928. 269 indexed citations

19.

Eisenberg, Jay D., Margaret S. Pepe, Margaret S. Pepe, et al.. (1997). A Comparison of Peak Sputum Tobramycin Concentration in Patients With Cystic Fibrosis Using Jet and Ultrasonic Nebulizer Systems. CHEST Journal. 111(4). 955–962. 101 indexed citations

20.

Marks, Cara, et al.. (1990). Plasma Tumor Necrosis Factor in Patients with Septic Shock: Mortality Rate, Incidence of Adult Respiratory Distress Syndrome, and Effects of Methylprednisolone Administration. American Review of Respiratory Disease. 141(1). 94–97. 253 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact